Prevalence of Helicobacter pylori antibodies in long-term dialysis patients

Background:  Helicobacter pylori has been reported to play an important role in the development of gastritis and gastric ulcer. Methods:  This study included 168 patients with end‐stage renal disease (ESRD; 30 non‐dialysis patients, 138 patients receiving dialysis; mean duration of dialysis: 57.3 ± ...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology (Carlton, Vic.) Vic.), 2004-04, Vol.9 (2), p.73-76
Main Authors: NAKAJIMA, FUMITAKA, SAKAGUCHI, MASAHIRO, OKA, HIROSHI, KAWASE, YOSHIO, SHIBAHARA, NOBUHISA, INOUE, TORU, UEDA, HARUHIKO, KATSUOKA, YOJI
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Antibodies, Bacterial - blood
dialysis
end-stage renal disease
Female
Helicobacter pylori
Helicobacter pylori - immunology
Histamine H2 Antagonists - pharmacology
Humans
Male
Middle Aged
prevalence
Renal Dialysis
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4999-8e13a536fb1090da55d5a3f0ad5114d92fae042019925dc2f3a3902a6a14ca203
cites cdi_FETCH-LOGICAL-c4999-8e13a536fb1090da55d5a3f0ad5114d92fae042019925dc2f3a3902a6a14ca203
container_end_page 76
container_issue 2
container_start_page 73
container_title Nephrology (Carlton, Vic.)
container_volume 9
creator NAKAJIMA, FUMITAKA
SAKAGUCHI, MASAHIRO
OKA, HIROSHI
KAWASE, YOSHIO
SHIBAHARA, NOBUHISA
INOUE, TORU
UEDA, HARUHIKO
KATSUOKA, YOJI
description Background:  Helicobacter pylori has been reported to play an important role in the development of gastritis and gastric ulcer. Methods:  This study included 168 patients with end‐stage renal disease (ESRD; 30 non‐dialysis patients, 138 patients receiving dialysis; mean duration of dialysis: 57.3 ± 61.7 months) and 138 control volunteers. We investigated the prevalence of H. pylori infection by measuring H. pylori antibody (IgG) levels. Results:  The prevalence of H. pylori infection was 62.3% in the control group, 53.3% in the non‐dialysis patients, and 36.9% in the dialysis patients. The percentage decreased with a reduction of renal function. In addition, the proportion of H. pylori‐positive patients decreased with the duration of dialysis, and the antibody titre was also significantly decreased. There was no association between long‐term oral administration of H2RA (H2 receptor antagonist) and the incidence of H. pylori infection. Conclusion:  Among dialysis patients, the proportion of H. pylori‐positive patients was low. An aetiological factor other than H2RA agents was suggested. Renal failure or dialysis treatment may influence H. pylori infection.
doi_str_mv 10.1111/j.1440-1797.2004.00239.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71790254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71790254</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4999-8e13a536fb1090da55d5a3f0ad5114d92fae042019925dc2f3a3902a6a14ca203</originalsourceid><addsrcrecordid>eNqNkE1vEzEQhi0Eoh_wF5BP3HY7_tqNJS6otGlF1eZQVKkXa7I7ixyc3WBvIPn3dUjUHstcZqR53rH8MMYFlCLX2aIUWkMhaluXEkCXAFLZcvOGHT8v3uZZSSiMMpMjdpLSAkDUshLv2ZEwYCpZmWP2fRbpDwbqG-JDx68o-GaYYzNS5KttGKLn2I9-PrSeEvc9D0P_s8jbJW89hm3yia9w9NSP6QN712FI9PHQT9mPy4v786vi5m56ff71pmi0tbaYkFBoVNXNBVho0ZjWoOoAWyOEbq3skEBLENZK0zayU6gsSKxQ6AYlqFP2eX93FYffa0qjW_rUUAjY07BOrs7fB2n0q6CE2laVURmc7MEmDilF6twq-iXGrRPgdsbdwu3Eup1YtzPu_hl3mxz9dHhjPV9S-xI8KM7Alz3w1wfa_vdhd3sxy0OOF_u4TyNtnuMYf7mqVrVxD7dTZy_r2eM3PXVGPQHfjZ2B</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20796653</pqid></control><display><type>article</type><title>Prevalence of Helicobacter pylori antibodies in long-term dialysis patients</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>NAKAJIMA, FUMITAKA ; SAKAGUCHI, MASAHIRO ; OKA, HIROSHI ; KAWASE, YOSHIO ; SHIBAHARA, NOBUHISA ; INOUE, TORU ; UEDA, HARUHIKO ; KATSUOKA, YOJI</creator><creatorcontrib>NAKAJIMA, FUMITAKA ; SAKAGUCHI, MASAHIRO ; OKA, HIROSHI ; KAWASE, YOSHIO ; SHIBAHARA, NOBUHISA ; INOUE, TORU ; UEDA, HARUHIKO ; KATSUOKA, YOJI</creatorcontrib><description>Background:  Helicobacter pylori has been reported to play an important role in the development of gastritis and gastric ulcer. Methods:  This study included 168 patients with end‐stage renal disease (ESRD; 30 non‐dialysis patients, 138 patients receiving dialysis; mean duration of dialysis: 57.3 ± 61.7 months) and 138 control volunteers. We investigated the prevalence of H. pylori infection by measuring H. pylori antibody (IgG) levels. Results:  The prevalence of H. pylori infection was 62.3% in the control group, 53.3% in the non‐dialysis patients, and 36.9% in the dialysis patients. The percentage decreased with a reduction of renal function. In addition, the proportion of H. pylori‐positive patients decreased with the duration of dialysis, and the antibody titre was also significantly decreased. There was no association between long‐term oral administration of H2RA (H2 receptor antagonist) and the incidence of H. pylori infection. Conclusion:  Among dialysis patients, the proportion of H. pylori‐positive patients was low. An aetiological factor other than H2RA agents was suggested. Renal failure or dialysis treatment may influence H. pylori infection.</description><identifier>ISSN: 1320-5358</identifier><identifier>EISSN: 1440-1797</identifier><identifier>DOI: 10.1111/j.1440-1797.2004.00239.x</identifier><identifier>PMID: 15056265</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Science Pty</publisher><subject>Adult ; Age Factors ; Aged ; Antibodies, Bacterial - blood ; dialysis ; end-stage renal disease ; Female ; Helicobacter pylori ; Helicobacter pylori - immunology ; Histamine H2 Antagonists - pharmacology ; Humans ; Male ; Middle Aged ; prevalence ; Renal Dialysis ; Time Factors</subject><ispartof>Nephrology (Carlton, Vic.), 2004-04, Vol.9 (2), p.73-76</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4999-8e13a536fb1090da55d5a3f0ad5114d92fae042019925dc2f3a3902a6a14ca203</citedby><cites>FETCH-LOGICAL-c4999-8e13a536fb1090da55d5a3f0ad5114d92fae042019925dc2f3a3902a6a14ca203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15056265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NAKAJIMA, FUMITAKA</creatorcontrib><creatorcontrib>SAKAGUCHI, MASAHIRO</creatorcontrib><creatorcontrib>OKA, HIROSHI</creatorcontrib><creatorcontrib>KAWASE, YOSHIO</creatorcontrib><creatorcontrib>SHIBAHARA, NOBUHISA</creatorcontrib><creatorcontrib>INOUE, TORU</creatorcontrib><creatorcontrib>UEDA, HARUHIKO</creatorcontrib><creatorcontrib>KATSUOKA, YOJI</creatorcontrib><title>Prevalence of Helicobacter pylori antibodies in long-term dialysis patients</title><title>Nephrology (Carlton, Vic.)</title><addtitle>Nephrology (Carlton)</addtitle><description>Background:  Helicobacter pylori has been reported to play an important role in the development of gastritis and gastric ulcer. Methods:  This study included 168 patients with end‐stage renal disease (ESRD; 30 non‐dialysis patients, 138 patients receiving dialysis; mean duration of dialysis: 57.3 ± 61.7 months) and 138 control volunteers. We investigated the prevalence of H. pylori infection by measuring H. pylori antibody (IgG) levels. Results:  The prevalence of H. pylori infection was 62.3% in the control group, 53.3% in the non‐dialysis patients, and 36.9% in the dialysis patients. The percentage decreased with a reduction of renal function. In addition, the proportion of H. pylori‐positive patients decreased with the duration of dialysis, and the antibody titre was also significantly decreased. There was no association between long‐term oral administration of H2RA (H2 receptor antagonist) and the incidence of H. pylori infection. Conclusion:  Among dialysis patients, the proportion of H. pylori‐positive patients was low. An aetiological factor other than H2RA agents was suggested. Renal failure or dialysis treatment may influence H. pylori infection.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Antibodies, Bacterial - blood</subject><subject>dialysis</subject><subject>end-stage renal disease</subject><subject>Female</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - immunology</subject><subject>Histamine H2 Antagonists - pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>prevalence</subject><subject>Renal Dialysis</subject><subject>Time Factors</subject><issn>1320-5358</issn><issn>1440-1797</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqNkE1vEzEQhi0Eoh_wF5BP3HY7_tqNJS6otGlF1eZQVKkXa7I7ixyc3WBvIPn3dUjUHstcZqR53rH8MMYFlCLX2aIUWkMhaluXEkCXAFLZcvOGHT8v3uZZSSiMMpMjdpLSAkDUshLv2ZEwYCpZmWP2fRbpDwbqG-JDx68o-GaYYzNS5KttGKLn2I9-PrSeEvc9D0P_s8jbJW89hm3yia9w9NSP6QN712FI9PHQT9mPy4v786vi5m56ff71pmi0tbaYkFBoVNXNBVho0ZjWoOoAWyOEbq3skEBLENZK0zayU6gsSKxQ6AYlqFP2eX93FYffa0qjW_rUUAjY07BOrs7fB2n0q6CE2laVURmc7MEmDilF6twq-iXGrRPgdsbdwu3Eup1YtzPu_hl3mxz9dHhjPV9S-xI8KM7Alz3w1wfa_vdhd3sxy0OOF_u4TyNtnuMYf7mqVrVxD7dTZy_r2eM3PXVGPQHfjZ2B</recordid><startdate>200404</startdate><enddate>200404</enddate><creator>NAKAJIMA, FUMITAKA</creator><creator>SAKAGUCHI, MASAHIRO</creator><creator>OKA, HIROSHI</creator><creator>KAWASE, YOSHIO</creator><creator>SHIBAHARA, NOBUHISA</creator><creator>INOUE, TORU</creator><creator>UEDA, HARUHIKO</creator><creator>KATSUOKA, YOJI</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200404</creationdate><title>Prevalence of Helicobacter pylori antibodies in long-term dialysis patients</title><author>NAKAJIMA, FUMITAKA ; SAKAGUCHI, MASAHIRO ; OKA, HIROSHI ; KAWASE, YOSHIO ; SHIBAHARA, NOBUHISA ; INOUE, TORU ; UEDA, HARUHIKO ; KATSUOKA, YOJI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4999-8e13a536fb1090da55d5a3f0ad5114d92fae042019925dc2f3a3902a6a14ca203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Antibodies, Bacterial - blood</topic><topic>dialysis</topic><topic>end-stage renal disease</topic><topic>Female</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - immunology</topic><topic>Histamine H2 Antagonists - pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>prevalence</topic><topic>Renal Dialysis</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NAKAJIMA, FUMITAKA</creatorcontrib><creatorcontrib>SAKAGUCHI, MASAHIRO</creatorcontrib><creatorcontrib>OKA, HIROSHI</creatorcontrib><creatorcontrib>KAWASE, YOSHIO</creatorcontrib><creatorcontrib>SHIBAHARA, NOBUHISA</creatorcontrib><creatorcontrib>INOUE, TORU</creatorcontrib><creatorcontrib>UEDA, HARUHIKO</creatorcontrib><creatorcontrib>KATSUOKA, YOJI</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology (Carlton, Vic.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NAKAJIMA, FUMITAKA</au><au>SAKAGUCHI, MASAHIRO</au><au>OKA, HIROSHI</au><au>KAWASE, YOSHIO</au><au>SHIBAHARA, NOBUHISA</au><au>INOUE, TORU</au><au>UEDA, HARUHIKO</au><au>KATSUOKA, YOJI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of Helicobacter pylori antibodies in long-term dialysis patients</atitle><jtitle>Nephrology (Carlton, Vic.)</jtitle><addtitle>Nephrology (Carlton)</addtitle><date>2004-04</date><risdate>2004</risdate><volume>9</volume><issue>2</issue><spage>73</spage><epage>76</epage><pages>73-76</pages><issn>1320-5358</issn><eissn>1440-1797</eissn><abstract>Background:  Helicobacter pylori has been reported to play an important role in the development of gastritis and gastric ulcer. Methods:  This study included 168 patients with end‐stage renal disease (ESRD; 30 non‐dialysis patients, 138 patients receiving dialysis; mean duration of dialysis: 57.3 ± 61.7 months) and 138 control volunteers. We investigated the prevalence of H. pylori infection by measuring H. pylori antibody (IgG) levels. Results:  The prevalence of H. pylori infection was 62.3% in the control group, 53.3% in the non‐dialysis patients, and 36.9% in the dialysis patients. The percentage decreased with a reduction of renal function. In addition, the proportion of H. pylori‐positive patients decreased with the duration of dialysis, and the antibody titre was also significantly decreased. There was no association between long‐term oral administration of H2RA (H2 receptor antagonist) and the incidence of H. pylori infection. Conclusion:  Among dialysis patients, the proportion of H. pylori‐positive patients was low. An aetiological factor other than H2RA agents was suggested. Renal failure or dialysis treatment may influence H. pylori infection.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Science Pty</pub><pmid>15056265</pmid><doi>10.1111/j.1440-1797.2004.00239.x</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1320-5358
ispartof Nephrology (Carlton, Vic.), 2004-04, Vol.9 (2), p.73-76
issn 1320-5358
1440-1797
language eng
recordid cdi_proquest_miscellaneous_71790254
source Wiley-Blackwell Read & Publish Collection
subjects Adult
Age Factors
Aged
Antibodies, Bacterial - blood
dialysis
end-stage renal disease
Female
Helicobacter pylori
Helicobacter pylori - immunology
Histamine H2 Antagonists - pharmacology
Humans
Male
Middle Aged
prevalence
Renal Dialysis
Time Factors
title Prevalence of Helicobacter pylori antibodies in long-term dialysis patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A21%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20Helicobacter%20pylori%20antibodies%20in%20long-term%20dialysis%20patients&rft.jtitle=Nephrology%20(Carlton,%20Vic.)&rft.au=NAKAJIMA,%20FUMITAKA&rft.date=2004-04&rft.volume=9&rft.issue=2&rft.spage=73&rft.epage=76&rft.pages=73-76&rft.issn=1320-5358&rft.eissn=1440-1797&rft_id=info:doi/10.1111/j.1440-1797.2004.00239.x&rft_dat=%3Cproquest_cross%3E71790254%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4999-8e13a536fb1090da55d5a3f0ad5114d92fae042019925dc2f3a3902a6a14ca203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20796653&rft_id=info:pmid/15056265&rfr_iscdi=true